ALK and non-small cell lung carcinoma: Compared to crizotinib, second-generation ALK TKIs, including alectinib, ceritinib, and brigatinib, have better sensitivity to ALK-positive NSCLC harboring a secondary mutation such as L1196M or G1269A (60).